Literature DB >> 23571107

The ras-GTPase activity of neurofibromin restrains ERK-dependent FGFR signaling during endochondral bone formation.

Koichiro Ono1, Matthew R Karolak, Jean de la Croix Ndong, Weixi Wang, Xiangli Yang, Florent Elefteriou.   

Abstract

The severe defects in growth plate development caused by chondrocyte extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) gain or loss-of-function suggest that tight spatial and temporal regulation of mitogen-activated protein kinase signaling is necessary to achieve harmonious growth plate elongation and structure. We provide here evidence that neurofibromin, via its Ras guanosine triphosphatase -activating activity, controls ERK1/2-dependent fibroblast growth factor receptor (FGFR) signaling in chondrocytes. We show first that neurofibromin is expressed in FGFR-positive prehypertrophic and hypertrophic chondrocytes during growth plate endochondral ossification. Using mice lacking neurofibromin 1 (Nf1) in type II collagen-expressing cells, (Nf1col2(-/-) mutant mice), we then show that lack of neurofibromin in post-mitotic chondrocytes triggers a number of phenotypes reminiscent of the ones observed in mice characterized by FGFR gain-of-function mutations. Those include dwarfism, constitutive ERK1/2 activation, strongly reduced Ihh expression and decreased chondrocyte proliferation and maturation, increased chondrocytic expression of Rankl, matrix metalloproteinase 9 (Mmp9) and Mmp13 and enhanced growth plate osteoclastogenesis, as well as increased sensitivity to caspase-9 mediated apoptosis. Using wildtype (WT) and Nf1(-/-) chondrocyte cultures in vitro, we show that FGF2 pulse-stimulation triggers rapid ERK1/2 phosphorylation in both genotypes, but that return to the basal level is delayed in Nf1(-/-) chondrocytes. Importantly, in vivo ERK1/2 inhibition by daily injection of a recombinant form of C-type natriuretic peptide to post-natal pups for 18 days was able to correct the short stature of Nf1col2(-/-) mice. Together, these results underscore the requirement of neurofibromin and ERK1/2 for normal endochondral bone formation and support the notion that neurofibromin, by restraining RAS-ERK1/2 signaling, is a negative regulator of FGFR signaling in differentiating chondrocytes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23571107      PMCID: PMC3999379          DOI: 10.1093/hmg/ddt162

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  105 in total

Review 1.  Osteopontin.

Authors:  J Sodek; B Ganss; M D McKee
Journal:  Crit Rev Oral Biol Med       Date:  2000

2.  Concentration of mRNA for the natriuretic peptide receptor-C in hypertrophic chondrocytes of the fetal mouse tibia.

Authors:  Y Yamashita; K Takeshige; A Inoue; S Hirose; A Takamori; H Hagiwara
Journal:  J Biochem       Date:  2000-02       Impact factor: 3.387

3.  Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.

Authors:  T Iwata; C L Li; C X Deng; C A Francomano
Journal:  Hum Mol Genet       Date:  2001-06-01       Impact factor: 6.150

4.  Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development.

Authors:  U I Chung; E Schipani; A P McMahon; H M Kronenberg
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

5.  Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain.

Authors:  Y Zhu; M I Romero; P Ghosh; Z Ye; P Charnay; E J Rushing; J D Marth; L F Parada
Journal:  Genes Dev       Date:  2001-04-01       Impact factor: 11.361

6.  Dwarfism and early death in mice lacking C-type natriuretic peptide.

Authors:  H Chusho; N Tamura; Y Ogawa; A Yasoda; M Suda; T Miyazawa; K Nakamura; K Nakao; T Kurihara; Y Komatsu; H Itoh; K Tanaka; Y Saito; M Katsuki; K Nakao
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

7.  A Ser(365)-->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia.

Authors:  L Chen; C Li; W Qiao; X Xu; C Deng
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

8.  Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.

Authors:  N Lau; M M Feldkamp; L Roncari; A H Loehr; P Shannon; D H Gutmann; A Guha
Journal:  J Neuropathol Exp Neurol       Date:  2000-09       Impact factor: 3.685

9.  A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures.

Authors:  Y X Zhou; X Xu; L Chen; C Li; S G Brodie; C X Deng
Journal:  Hum Mol Genet       Date:  2000-08-12       Impact factor: 6.150

10.  A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos.

Authors:  T Iwata; L Chen; C Li; D A Ovchinnikov; R R Behringer; C A Francomano; C X Deng
Journal:  Hum Mol Genet       Date:  2000-07-01       Impact factor: 6.150

View more
  9 in total

1.  Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth.

Authors:  Mylène Tajan; Julie Pernin-Grandjean; Nicolas Beton; Isabelle Gennero; Florence Capilla; Benjamin G Neel; Toshiyuki Araki; Philippe Valet; Maithé Tauber; Jean-Pierre Salles; Armelle Yart; Thomas Edouard
Journal:  Hum Mol Genet       Date:  2018-07-01       Impact factor: 6.150

2.  Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.

Authors:  Jean de la Croix Ndong; David M Stevens; Guillaume Vignaux; Sasidhar Uppuganti; Daniel S Perrien; Xiangli Yang; Jeffry S Nyman; Eva Harth; Florent Elefteriou
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

3.  The reduced osteogenic potential of Nf1-deficient osteoprogenitors is EGFR-independent.

Authors:  S E Tahaei; G Couasnay; Y Ma; N Paria; J Gu; B F Lemoine; X Wang; J J Rios; F Elefteriou
Journal:  Bone       Date:  2017-10-12       Impact factor: 4.398

4.  FGFR1 signaling in hypertrophic chondrocytes is attenuated by the Ras-GAP neurofibromin during endochondral bone formation.

Authors:  Matthew R Karolak; Xiangli Yang; Florent Elefteriou
Journal:  Hum Mol Genet       Date:  2015-01-23       Impact factor: 6.150

5.  Glycoprotein nonmetastatic melanoma protein B extracellular fragment shows neuroprotective effects and activates the PI3K/Akt and MEK/ERK pathways via the Na+/K+-ATPase.

Authors:  Yoko Ono; Kazuhiro Tsuruma; Masafumi Takata; Masamitsu Shimazawa; Hideaki Hara
Journal:  Sci Rep       Date:  2016-03-18       Impact factor: 4.379

6.  Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.

Authors:  Jirko Kühnisch; Jong Seto; Claudia Lange; Susanne Schrof; Sabine Stumpp; Karolina Kobus; Julia Grohmann; Nadine Kossler; Peter Varga; Monika Osswald; Denise Emmerich; Sigrid Tinschert; Falk Thielemann; Georg Duda; Wenke Seifert; Thaqif El Khassawna; David A Stevenson; Florent Elefteriou; Uwe Kornak; Kay Raum; Peter Fratzl; Stefan Mundlos; Mateusz Kolanczyk
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

7.  Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.

Authors:  Jean de la Croix Ndong; Alexander J Makowski; Sasidhar Uppuganti; Guillaume Vignaux; Koichiro Ono; Daniel S Perrien; Simon Joubert; Serena R Baglio; Donatella Granchi; David A Stevenson; Jonathan J Rios; Jeffry S Nyman; Florent Elefteriou
Journal:  Nat Med       Date:  2014-07-06       Impact factor: 53.440

8.  Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.

Authors:  A Carlier; H Brems; J M A Ashbourn; I Nica; E Legius; L Geris
Journal:  Sci Rep       Date:  2016-01-29       Impact factor: 4.379

9.  The Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Pathway in Osteoblasts.

Authors:  Matthew B Greenblatt; Jae-Hyuck Shim; Seoyeon Bok; Jung-Min Kim
Journal:  J Bone Metab       Date:  2022-02-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.